ПРОТОКОЛ ВЕДЕНИЯ ПАЦИЕНТОВ С ЮВЕНИЛЬНЫМ АРТРИТОМ

Представлен протокол ведения пациентов с ювенильным артритом в амбулаторно-поликлинических и стационарных условиях, разработанный на основе международных рекомендаций и собственных данных. Протокол включает подробный план обследования пациентов с подозрением на ювенильный артрит и пациентов с уже установленным диагнозом; алгоритм назначения, контроля эффективности и токсичности иммунодепрессантов и генно-инженерных биологических препаратов

1. Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6 th ed. Philadelphia: Saunders Elsevier. 2010. Р. 794.

2. Baranov A. A. Pediatrics. Clinical recommendations. Moscow: GEOTAR-Media. 2009. Pp. 387–420.

3. Alekseyeva Ye. I., Litvitskiy P. F. Juvenile rheumatoid arthritis. Etiology, pathogenesis, clinical symptoms, algorithms of diagnostics and treatment. Moscow: VEDI. 2007. 360 pp.

4. Alekseyeva Ye. I., Valiyeva S. I., Bzarova T. M. Efficacy and safety of recurrent courses of rituximab in treatment of refractory juvenile rheumatoid arthritis. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 8 (5): pp. 14–25.

5. Duckers G., Niehues T. The importance of biologicals in the treatment of SoJIA. Z. Rheumatol. 2010 Aug; 69 (6): 505–515.

6. Horneff G. Juvenile arthritides. Z. Rheumatol. 2010 Oct; 69 (8): 719–736.

7. Bergman G. J., Hochberg M. C., Boers M. et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to diseasemodifying antirheumatic drugs. Semin. Arthritis Rheum. 2010; 39 (6): 425–441.

8. Nam J. L., Winthrop K. L., van Vollenhoven R. F. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 2010; 69 (6): 976–986.

9. Papagoras C., Voulgari P. V., Drosos A. A. Strategies after the failure of the first antitumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun. Rev. 2010; 9 (8): 574–582.

10. Jones G. The Ambition trial: tocilizumab monotherapy for rheumatoid arthritis. Expert. Rev. Clin. Immunol. 2010, Mar; 6 (2): 189–195.

11. Frey N., Grange S., Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J. Clin. Pharmacol. 2010; 50 (7): 754–766.

12. Hirabayashi Y., Ishii T., Harigae H. Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol. Int. 2010; 30 (8): 1041–1048.

13. De Benedetti F., Brunner H., Ruperto N. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012; 367 (25): 2385–2395.

14. Alekseyeva Ye. I., Denisova R. V., Valiyeva S. I. et al. Efficacy and safety of tocilizumab in patients with severe systemic juvenile idiopathic arthritis. Voprosi sovremennoi pediatrii — Current Pediatrics. 2011; 10 (3): pp. 24–31.

15. Furst D. E., Keystone E. C., Braun J. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011; 70 (Suppl. 1): i2–i36.

16. Otten M., Prince F., Twilt M. et al. Delaed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J. Rheumatol. 2010; 37: 665–667.

17. Lovell D. J., Reiff A., Ilowite N. T., Wallace C. A. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008 May; 58 (5): 1496–1504.

18. McInnes I. B., O'Dell J. R. State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 2010; 69 (11): 1898–1906.

19. Klein A., Hornef G. Treatment strategies for juvenile idiopathic arthritis. Expert. Opin. Pharmacother. 2009; 10 (18): 3049–3060.

20. Lovell D. J., Ruperto N., Reiff A. et al. Long-term efficacy and safety of adalimumab for up to 6 years in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2011; 63 (10 Suppl): S99.

21. Breda L., Del Torto M., De Sanctis S., Chiarelli F. (2011) Biologics in children’s autoimmune disorders: Efficacy and safety. Eur J Pediatr. 2011; 170: 157–167.

22. Foeldvari I., Nielsen S., Kummerle-Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J. Rheumatol. 2007; 34 (5): 1146–1150.

23. Ruperto N., Lovell D. J., Reiff A., Gamir M., Higgins G., KonePaut I. et al. Longterm efficacy and safety of Adalimumab in 4–12 year old patients with juvenile idiopathic arthritis. Pediatr Rheumatol. 2011; 9 (Suppl. 1): O26.

24. Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: An open label study. Ann Rheum Dis. 2003; 62: 245–247.

25. Heiligenhaus A. et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012; 32: 1121–1133.

26. Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011 Apr; 63 (4): 465–482.

27. Wallace C. A., Giannini E. H., Huang B. et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken). 2011 Jul; 63 (7): 929–936.

28. Petty R. E., Southwood T. R., Manners P., Baum J. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004 Feb; 31 (2): 390–392